Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy
Abstract Interindividual heterogeneity in the disease progression of HIV-1-infected patients receiving long-term antiretroviral therapy suggests that some host-related factors may have limited treatment efficacy. To understand the nature of factors contributing to treatment failure, we performed a r...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0a9c0dd248034bcfa50ff8cdab280a48 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0a9c0dd248034bcfa50ff8cdab280a48 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0a9c0dd248034bcfa50ff8cdab280a482021-12-02T12:32:59ZEscape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy10.1038/s41598-017-05594-52045-2322https://doaj.org/article/0a9c0dd248034bcfa50ff8cdab280a482017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-05594-5https://doaj.org/toc/2045-2322Abstract Interindividual heterogeneity in the disease progression of HIV-1-infected patients receiving long-term antiretroviral therapy suggests that some host-related factors may have limited treatment efficacy. To understand the nature of factors contributing to treatment failure, we performed a retrospective cohort study of 45 chronically HIV-1-infected individuals sharing a similar demographics and route of infection, compared the differences between virologically suppressed (VS) and treatment failure (TF) patients with respect to clinical, immunological and virological characteristics. We found that the baseline diversity of HIV-1 env quasispecies was the major difference between VS and TF group, and higher baseline diversity in TF patients. We further predicted TF-related env mutations using a selection pressure-based approach, followed by an analysis of these mutations based on the available three-dimensional structures of gp120/gp41 or their complexes with neutralizing antibodies. Notably, almost all of the identified residues could be mapped to the epitopes of known HIV-1 neutralizing antibodies, especially the epitopes of broadly neutralizing antibodies, and these mutations tended to compromise antibody-antigen interactions. These results indicate that the escape of HIV-1 from host humoral immunity may play a direct role in TF in long-term antiretroviral-experienced patients and that based on env gene sequence of the viruses in the patients.Yabo OuyangQianqian YinWei LiZhenpeng LiDesheng KongYanling WuKunxue HongHui XingYiming ShaoShibo JiangTianlei YingLiying MaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-12 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Yabo Ouyang Qianqian Yin Wei Li Zhenpeng Li Desheng Kong Yanling Wu Kunxue Hong Hui Xing Yiming Shao Shibo Jiang Tianlei Ying Liying Ma Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy |
| description |
Abstract Interindividual heterogeneity in the disease progression of HIV-1-infected patients receiving long-term antiretroviral therapy suggests that some host-related factors may have limited treatment efficacy. To understand the nature of factors contributing to treatment failure, we performed a retrospective cohort study of 45 chronically HIV-1-infected individuals sharing a similar demographics and route of infection, compared the differences between virologically suppressed (VS) and treatment failure (TF) patients with respect to clinical, immunological and virological characteristics. We found that the baseline diversity of HIV-1 env quasispecies was the major difference between VS and TF group, and higher baseline diversity in TF patients. We further predicted TF-related env mutations using a selection pressure-based approach, followed by an analysis of these mutations based on the available three-dimensional structures of gp120/gp41 or their complexes with neutralizing antibodies. Notably, almost all of the identified residues could be mapped to the epitopes of known HIV-1 neutralizing antibodies, especially the epitopes of broadly neutralizing antibodies, and these mutations tended to compromise antibody-antigen interactions. These results indicate that the escape of HIV-1 from host humoral immunity may play a direct role in TF in long-term antiretroviral-experienced patients and that based on env gene sequence of the viruses in the patients. |
| format |
article |
| author |
Yabo Ouyang Qianqian Yin Wei Li Zhenpeng Li Desheng Kong Yanling Wu Kunxue Hong Hui Xing Yiming Shao Shibo Jiang Tianlei Ying Liying Ma |
| author_facet |
Yabo Ouyang Qianqian Yin Wei Li Zhenpeng Li Desheng Kong Yanling Wu Kunxue Hong Hui Xing Yiming Shao Shibo Jiang Tianlei Ying Liying Ma |
| author_sort |
Yabo Ouyang |
| title |
Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy |
| title_short |
Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy |
| title_full |
Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy |
| title_fullStr |
Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy |
| title_full_unstemmed |
Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy |
| title_sort |
escape from humoral immunity is associated with treatment failure in hiv-1-infected patients receiving long-term antiretroviral therapy |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/0a9c0dd248034bcfa50ff8cdab280a48 |
| work_keys_str_mv |
AT yaboouyang escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT qianqianyin escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT weili escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT zhenpengli escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT deshengkong escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT yanlingwu escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT kunxuehong escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT huixing escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT yimingshao escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT shibojiang escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT tianleiying escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy AT liyingma escapefromhumoralimmunityisassociatedwithtreatmentfailureinhiv1infectedpatientsreceivinglongtermantiretroviraltherapy |
| _version_ |
1718393900028133376 |